7 results about "Myc proteins" patented technology

Provided are a c-Myc protein inhibitor, and a preparation method therefor and use thereof. The c-Myc protein inhibitor selectively inhibits c-Myc protein. Therefore, the inhibitor can be used for prevention and treatment of diseases related to c-Myc protein disorders, such as cancers, cardiovascular and cerebrovascular diseases, diseases related to virus infection.

The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation can degrade various proteins including c-Myc protein, and therefore can be used for prevention and treatment of diseases related to disorders of various proteins including c-Myc protein, such as cancer; cardiovascular and cerebrovascular diseases, and viral infection-related diseases.

The application discloses application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma, utilizes CCK8 cell activity experiment to detect the inhibition ability of YW2301 on Raji and CA46 cell proliferation, constructs a NON / SCID subcutaneous transplantation tumor model by using a Raji cell line, evaluates the therapeutic significance of YW2301 on Burkitt lymphoma, YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of the transplantation tumor, and adopts immunohistochemical staining to detect the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma transplantation tumor tissue section, YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma tissue, and further proves that YW2301 can be used as a candidate small molecule for targeted treatment of Burkitt lymphoma.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an MYC mRNA translation inhibitor in preparation of a medicine for preventing and / or treating osteoarthritis. The MYC mRNA translation inhibitor is selected from biological materials capable of inhibiting or blocking the MYC mRNA translation process, reducing the MYC protein synthesis efficiency or interfering the MYC mRNA steady state level. The invention provides a novel molecular target capable of being used for treating osteoarthritis and a medicine application scheme of the molecular target.

Disclosed is a compound as shown in general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, and diastereomer thereof. The compound of the present invention significantly improves the degradation effect of GSPT1 protein and the anti-proliferative inhibition activity of AML and solid tumor cells. Therefore, the compound of the present invention can be used in the preparation of a medicament for treating or preventing diseases related to GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutation, expression imbalance, and allostery and functional abnormalities; in addition, said compound can be used to prepare a GSPT1 degrading agent.

The application discloses a small molecule degrading agent of aryl formamides and application thereof, and has a structure shown in general formula I or a pharmaceutically acceptable salt, an isotopically labeled compound thereof. The compound of the application has a targeted degradation activity on MYC protein, and has a significant proliferation inhibiting activity on various solid tumor cells such as neuroblastoma and rhabdomyosarcoma. The compound of the application can be used for preparing a degrading agent targeting MYC protein, and can also be used for preparing a drug for treating diseases related to MYC gene amplification, fusion, mutation, expression imbalance, conformational change and function abnormality.

The application provides an isolated polypeptide and application thereof, and the polypeptide comprises an amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2. The isolated polypeptide can specifically bind to a c-Myc protein, destroy the stabilizing effect of RALY on the c-Myc protein, promote the degradation of the c-Myc protein through a ubiquitin-proteasome pathway, inhibit the proliferation of cancer cells, reduce the survival ability of the cancer cells, and can effectively prevent and / or treat tumors.